Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TtbioROCO:6493 -5.15%60 FCF Margin % is -24.61% as of Dec. 2025. GuruFocus rates ROCO:6493 with a GF Score™ of 60/100 and a GF Value™ of NT$19.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Ttbio ranks worse than 66.91% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ttbio's Free Cash Flow for the
six
months ended in Dec. 2025 was NT$-45.8 Mil. Ttbio's Revenue for the
six
months ended in Dec. 2025 was NT$186.0 Mil. Therefore, Ttbio's FCF Margin % for the quarter that ended in Dec. 2025 was -24.61%.
The historical rank and industry rank for Ttbio's FCF Margin % or its related term are showing as below:
ROCO:6493'
s FCF Margin % Range Over the Past 10 Years
Min: -12.54 Med: 3.7 Max: 15.08
Current: -12.54
During the past 13 years, the highest FCF Margin % of Ttbio was 15.08%. The lowest was -12.54%. And the median was 3.70%.
ROCO:6493's FCF Margin % is ranked worse than 66.91% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: -0.57
vs ROCO:6493: -12.54
Ttbio FCF Margin % Related Terms
Ttbio FCF Margin % Historical Data
* Premium members only.
The historical data trend for Ttbio's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6493 vs ISRG, BDX, MDLN: FCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Ttbio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ttbio FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ttbio's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Ttbio's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ttbio (ROCO:6493) has a FCF Margin % of -24.61% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ttbio and its competitors. According to the industry distribution chart, Ttbio ranks #546 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 66.9%.
Is Ttbio's FCF Margin % too high?
Ttbio's current FCF Margin % is -24.61%. Based on the distribution chart, Ttbio ranks #546 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ttbio has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ttbio's FCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ttbio ranks #546 out of 816 companies for FCF Margin %. This places Ttbio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ttbio and its competitors. Ttbio's current FCF Margin % is -24.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ttbio stock overvalued right now?
Based on GuruFocus' analysis, Ttbio (ROCO:6493) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$19.62, compared to a current price of NT$48.85 — trading 149% above its estimated fair value. The current FCF Margin % is -24.61%. Ttbio's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Ttbio (ROCO:6493), the current FCF Margin % is -24.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ttbio (ROCO:6493) Overvalued in 2026?
Based on GuruFocus' analysis, Ttbio stock appears to be overvalued.
The current stock price of NT$48.85 is trading 149% above its estimated GF Value™ of NT$19.62.
GuruFocus considers Ttbio to be Significantly Overvalued.
Key valuation signals for ROCO:6493:
FCF Margin %: -24.61%
GF Value™: NT$19.62 vs. price of NT$48.85 (149% above fair value)
No single metric tells the full story. See the ROCO:6493 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ttbio Corp is a Taiwan based company engaged in the manufacturing of dental products and accessories. Its products include High-Speed Handpiece Series, Low-Speed Handpiece Series, Dental Spare Parts, Service Rotor, and Maintenance Unit among others.
60GF Score
Get the complete analysis for ROCO:6493
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6493 has been successfully added to your 
